Sunshine Biopharma Inc. — Form 8-K
Filed July 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 56/100
What the filing says
Sunshine Biopharma Inc. (trading symbol SBFM, market cap ~$7.1M) entered into an At-The-Market Issuance Sales Agreement dated July 20, 2026 with Aegis Capital Corp., permitting the company to issue and sell up to $4,000,000 of common stock ($0.001 par value) over time at market prices. Aegis Capital will serve as exclusive sales agent and receive 3% commission on gross proceeds. The agreement is effective until all shares are sold or either party terminates per Section 13 provisions.
Why this rating
ATM offering of $4M represents 56% of current market cap—material fundraising capacity. Non-dilutive pricing mechanism reduces immediate shareholder dilution risk, but maximum dilution exposure is material. Standard equity financing structure; not transformational but meaningful for $7.1M company.
Extracted items
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.